Inmune Bio, Inc 8-K, filed Mar 4, 2020
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on March 4, 2020, reporting on events of February 27, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2020
| INMUNE BIO INC. | ||
| (Exact name of registrant as specified in charter) |
| Nevada | 001-38793 | 47-5205835 | ||
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
1200 Prospect Street, Suite 525 La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | INMB | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On February 27, 2020, INmune Bio, Inc. (the “Company”) issued a press release announcing that it had scheduled a conference call to Report 2019 Fourth Quarter and Full Year Financial Results
The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
The exhibits listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
| Exhibit Number |
Description | |
| 99.1 | INmune Bio, Inc. Press Release dated February 27, 2020 |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: March 3, 2020 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
2
Exhibit 99.1
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat disease, today announced that it will release financial results for its 2019 fourth quarter and year end on Wednesday, March 11, 2020.
The Company will hold a conference call at 11AM Eastern (U.S.) time on March 11, 2020. To participate in the live conference call, please dial 1-877-407-2988 five minutes prior to the scheduled conference call time. International callers should dial 1-201-389-0923.
Participants can also use this link for instant telephone access to the event.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting
the innate immune system. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s
response to their disease - immune priming platform and DN-TNF platform. The immune priming platform is a Natural Killer (NK) cell
therapeutic that primes the patient’s NK cells to attack residual disease – the cause of cancer relapse. The DN-TNF
platform includes programs in cancer, neurodegenerative disease and NASH. INB03 modifies the tumor microenvironment which
often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors and trastuzumab. XPro1595 targets microglial
activation, nerve cell death and synaptic dysfunction associated with neurodegenerative disease. LivNate modifies metabolic and
immunologic pathology that contributes to the development and progression of NASH. To learn more, please visit www.inmunebio.com.
Forward-Looking Statements
There is no guarantee that any specific outcome will be achieved. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number
of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INBO3, LivNate, INKmune and XPro1595
are starting or still in clinical trials and have not been approved and there cannot be any assurance that they will be approved
or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug
for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product commercialization; and, the Company’s business, research, product
development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described
in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual
Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s
Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any
event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
James Carbonara, Hayden IR
(646) 755-7412
james@haydenir.com